
Emergency Care for the OB Patient: Hypertension in Pregnancy

Anne Erickson, MD • Ob-Gyn HEAL Fellow • 12.16.21

I have no financial interests or relationships to disclose.

Context: OB ED Readiness



Context: OB ED Readiness

- Postpartum hemorrhage
- Breech vaginal delivery
- Shoulder dystocia
- Trauma in pregnancy
- Hypertension in pregnancy
- Normal labor and delivery

Objectives: Hypertension in pregnancy


- (1) the Ob-Gyn perspective
 - Epidemiology, pathophysiology, diagnosis, management
- (2) the ED perspective
 - Discuss an approach to identifying, triaging, managing OB HTN in the ED
 - Additional thoughts on OB HTN
- (3) COVID in pregnancy
 - Complications, ED considerations, vaccination, antibodies

(1) Ob-Gyn

Epidemiology

- Hypertensive disorders of pregnancy (preeclampsia and related diagnoses) are a leading cause of maternal and perinatal morbidity and mortality
 - Seizures, strokes, IUFD
- 16% of maternal deaths and ~9% of fetal demises
- HTN complicates 2-8% of pregnancies globally
- Rates are increasing

Pathophysiology



New-onset hypertension in pregnancy

Sometimes accompanied by proteinuria

Sometimes accompanied by signs of damage to other organs (liver, kidney)

Mechanism not well-understood, but a disorder of placental \rightarrow vascular dysfunction

| Condition | Diagnosis | Treatment | Delivery |
|-----------------------------|--|--|------------------------------------|
| Gestational hypertension | Systolic BP >/= 140 or diastolic BP >/= 90 on two occasions at least 4 hours apart after 20 weeks' gestation | No antihypertensive treatment unless BPs become severe-range (>/= 160 systolic or >/= 110 diastolic) | Without other comorbidities, 37wga |
| | | Blood pressure monitoring Antenatal testing Growth ultrasounds | |

| Condition | Diagnosis | Treatment | Delivery |
|--|--|--|------------------------------------|
| Preeclampsia without severe features | Gestational hypertension PLUS proteinuria: >/=300mg on a 24h urine collection, P:C ratio of >/= 0.3, Urine dip with >/= 2+ | No antihypertensive treatment unless BPs become severe-range (>/= 160 systolic or >/= 110 diastolic) | Without other comorbidities, 37wga |
| | protein | Blood pressure monitoring Antenatal testing Growth ultrasounds | |

| Condition | Diagnosis | Treatment | Delivery |
|-----------------------------------|---|---|--|
| Preeclampsia with severe features | Severe-range blood pressures (systolic BP >/= 160 or diastolic BP >/= 110; do not need to wait 4h) OR mild-range BPs plus any of the following: - Plts <100k - Cr >1.1 or 2x baseline - LFTs 2x ULN - Persistent RUQ/epigastric pain - Persistent headache - Visual changes - Pulmonary edema | Antihypertensives for severe-range blood pressures Magnesium sulfate infusion for seizure prophylaxis If not delivering immediately, inpatient management for BP monitoring, antenatal testing, growth US, labs at least q12h until stable. | If stable and without other comorbidities, expectant management until 34wga. |

| Condition | Diagnosis | Treatment | Delivery |
|--|---|---|-------------------------------|
| HELLP (hemolysis, elevated liver enzymes, low platelets syndrome) | Considered a severe form of pre-E, but can present without HTN or proteinuria. Main presenting symptoms are RUQ pain and malaise (90%) and N/V (50%). ACOG's criteria (need 3/3): (1) LDH >/= 600IU/L (2) AST/ALT >/= 2x ULN (3) Plts <100k | Antihypertensives if indicated for severe-range BPs Magnesium sulfate infusion for seizure prophylaxis Labs at least q12h (usually q6h) | After maternal stabilization. |

| Condition | Diagnosis | Treatment | Delivery |
|-----------|---|--|-------------------------------|
| Eclampsia | New-onset tonic-clonic, focal, or multifocal seizures in pregnancy in the absence of other causative conditions | Maternal stabilization Magnesium sulfate IM vs IV | After maternal stabilization. |

(2) ED

OB ED Algorithm: HTN in Pregnancy

Pregnant >20wga with:

Elevated BPs (>/=140/90) RUQ/epigastric pain HA or visual changes Significant or new-onset edema

Evaluation:

Serial BP measurements Labs: CBC, CMP, LDH, P:C History: Evaluate for severe

History: Evaluate for severe features

- RUQ/epigastric pain
- HA/visual changes

Exam: Pulmonary, reflexes, extremities

Fetal assessment



No severe features:



No immediate treatment Consult OB Inpt vs outpatient follow-up

Any severe features:

BPs >/= 160/110 OR:

- Plts <100k
- Cr >1.1 or 2x baseline
- LFTs 2x ULN or RUQ pain (persistent)
- Pulmonary edema
- Headache (persistent)
- Visual changes (persistent)
- HELLP criteria met (LDH>/=600 +plts +LFTs)



Initiate antihypertensives for severe-range BPs:

- Labetalol 20mg IV
- Hydralazine 5mg IV,
- Nifedipine 10mg PO

Serial BP monitoring

MgSO4 4-6g loading dose → 1-2g/hr Fetal monitoring Consult OB

Inpatient management vs delivery

Antihypertensive agents

Table 3. Antihypertensive Agents Used for Urgent Blood Pressure Control in Pregnancy

| | - | | - |
|-----------------------------------|--|---|-----------------|
| Drug | Dose | Comments | Onset of Action |
| Labetalol | 10–20 mg IV, then 20–80 mg every 10–30 minutes to a maxi- mum cumulative dosage of 300 mg; or constant infusion 1–2 mg/min IV | Tachycardia is less common with fewer adverse effects. | 1–2 minutes |
| | | Avoid in women with asthma, preexisting myocardial disease, decompensated cardiac function, and heart block and bradycardia. | |
| Hydralazine | 5 mg IV or IM, then 5–10 mg IV every 20–40 minutes to a maxi- mum cumulative dosage of 20 mg; or constant infusion of 0.5–10 mg/hr | Higher or frequent dosage associated with maternal hypotension, headaches, and abnormal fetal heart rate tracings; may be more common than other agents. | 10–20 minutes |
| Nifedipine (immediate release) | 10–20 mg orally, repeat in 20 minutes if needed; then 10–20 mg every 2–6 hours; maximum daily dose is 180 mg | May observe reflex tachycardia and headaches | 5–10 minutes |

Abbreviations: IM, intramuscularly; IV, intravenously.

Trigger: If severe elevations (SBP ≥160 or DBP ≥ 110) persist* for 15 min or more OR If two severe elevations are obtained within 15 min and tx is clinically indicated



- Every 10 minutes for 1 hour
 - Then every 15 minutes for 1 hour
 - Then every 30 minutes for 1 hour
 - Then every hour for 4 hours



Institute additional BP monitoring per specific order

- · Notify provider after one severe BP value is obtained
- · Institute fetal surveillance if viable
- · Hold IV labetalol for maternal pulse under 60
- Maximum cumulative IV-administered dose of labetalol should not exceed 300 mg in 24 hours
- There may be adverse effects and contraindications. Clinical judgement should prevail.

- * Two severe readings more than 15 minutes and less than 60 minutes apart
- * Avoid parenteral labetalol with active* asthma, heart disease, or congestive heart failure; use with caution with history of asthma. May cause neonatal bradycardia.
- * "Active asthma" is defined as:
- A symptoms at least once a week, or
- (B) use of an inhaler, corticosteroids for asthma during the pregnancy, or
- © any history of intubation or hospitalization for asthma.
- § Hydralazine may increase risk of maternal hypotension.

Magnesium sulfate

- The first-line medication for prevention of seizures (NNT = 63 with severe features)
- Prevents seizures and seizure recurrences; does not stop an ongoing seizure
- Inhibits NMDA receptors → Decreases neuronal excitability? Causes cerebral vasodilation?
- Dosing:
 - 4-6g 10% MgSO4 IV (100mL solution) over 10 min → maintenance 1-2g/hr
 - No IV: 10g IM (5g in each buttock)
- Monitor for toxicity (UOP, VS, reflexes), especially with renal impairment:
 - 5-9 mg/dL therapeutic
 - >9 loss of patellar reflexes
 - >12 respiratory paralysis
 - >30 cardiac arrest
- Antidote: Calcium gluconate 10mL (10% IV, 1g total, over 3 min)

Eclampsia

- New-onset, tonic-clonic, multifocal seizure in pregnancy in the absence of other causes
- Basic supportive measures
- Magnesium sulfate:
 - If already infusing: +2g IV over 15-20min
 - If IV access: 6g IV bolus over 15-20 min, then 2g/hr ongoing
 - o If no IV: 10g IM (5g IM in each buttock)
- If recurrent: give an additional 2-4g IV bolus / 5min
- If refractory (still seizing 20min after bolus or >2 recurrences)
 - o alternate medications: Lorazepam 2-4mg IV x1, repeat 10-15 min (?sodium amobarbital, ?thiopental, ?phenytoin)
 - intubation
 - imaging
 - ICU admission
- Deliver promptly after maternal stabilization
 - Eclampsia is *not* always an indication for cesarean delivery

EXAMPLE

Eclampsia Checklist

| Mercanipora Circuit | IDC |
|---|--|
| Call for Assistance | |
| □ Designate ○ Team leader ○ Checklist reader/recorder ○ Primary RN | Magnesium Sulfate Contraindications: Myasthenia gravis; avoid with pulmonary edema, use caution with renal failure IV access: |
| ☐ Ensure side rails up | Load 4-6 grams 10% magnesium sulfate in 100 mL solution over 20 min |
| Protect airway and improve oxygenation: Maternal pulse oximetry Supplemental oxygen (100% non-rebreather) Lateral decubitis position | Label magnesium sulfate; Connect to labeled infusion pump Magnesium sulfate maintenance 1-2 grams/hour No IV access: 10 grams of 50% solution IM (5 g in each buttock) |
| ☐ Bag-mask ventilation available ☐ Suction available | Antihypertensive Medications |
| ☐ Continuous fetal monitoring | For SBP ≥ 160 or DBP ≥ 110 (See SMI algorithms for complete management when necessary to move to another agent after 2 doses.) |
| ☐ Place IV; Draw preeclampsia labs | Labetalol (initial dose: 20mg); Avoid parenteral labetalol |
| Ensure medications appropriate given patient history | with active asthma, heart disease, or congestive heart failure; use with caution with history of asthma Hydralazine (5-10 mg IV* over 2 min); May increase risk |
| Administer magnesium sulfate | of maternal hypotension |
| Administer antihypertensive therapy if appropriate | Oral Nifedipine (10 mg capsules); Capsules should be administered orally, not punctured or otherwise administered sublingually |
| Develop delivery plan, if appropriate | * Maximum cumulative IV-administered doses should not exceed 220 mg labetalol or 25 mg hydralazine in 24 hours |
| Debrief patient, family, and obstetric team | Note: If persistent seizures, consider anticonvulsant medications and additional workup |
| | Anticonvulsant Medications |
| "Active asthma" is defined as: (a) symptoms at least once a week, or (b) use of an inhaler, corticosteroids for asthma during the pregnancy, or (c) any history of intubation or hospitalization | For recurrent seizures or when magnesium sulfate contraindicated Lorazepam (Ativan): 2-4 mg IV x 1, may repeat once after 10-15 min Diazepam (Valium): 5-10 mg IV q 5-10 min to maximum dose 30 mg |
| for asthma. | For Persistent Seizures Neuromuscular block and intubate Obtain radiographic imaging ICU admission Consider anticonvulsant medications |

Safe Motherhood Initiative



Eclampsia Algorithm Call for help 1. Position patient in left lateral decubitus position 2. Establish open airway and maintain breathing 3. Check Oxygen level 4. Check blood pressure and pulse 5. Obtain IV access: 1 or 2 large-bore IV catheters Magnesium Sulfate 4-6 gram IV loading dose If the patient seizes again over 15-20 minutes; followed while on magnesium sulfate by a 2 gram/hour maintenance dose: maintenance dose if renal function is normal 1. Maintain airway and oxygenation 2. Give a 2nd loading dose of magnesium sulfate 2 grams over 5 If patient has a recurrent minutes seizure after a 2nd loading 3. Observe for signs of magnesium dose of magnesium sulfate toxicity consider the following: Resolution of seizures: 1. Maintain magnesium Discontinuation of 1. Midazolam (versed) 1-2 mg IV (can repeat in 5-10 sulfate infusion until 24 hours therapy: minutes) OR after the last seizure or after 2. Lorazepam (ativan) 4 mg IV over 2-5 minutes delivery, whichever is later Severe preeclampsia (can repeat in 5-15 minutes to maximum of 8 mg in 2. Assess for any signs of 12 hours) OR and eclampsia: neurologic injury/focal deficit: 24 hours after delivery or 3. Diazepam (valium) 5-10 mg IV slowly (can repeat head imaging should be after last seizure every 15 minutes up to 30 mg) OR considered if neurologic injury 4. Phenytoin (dilantin) 1000 mg IV over 20 minutes is suspected NOTE: Administration 5. Monitor respiration and BP, ECG and signs of 3. Once the patient is beyond 24 hours may be magnesium toxicity. Phenytoin may cause QRS or stabilized preparations should indicated if the patient QT prolongation. be made for delivery: mode of shows no signs of delivery is dependent upon improvement clinical circumstances NOTE: These recommendations can be modified for surrounding the pregnancy use as each institution requires.

Final thoughts on OB HTN...

- Not always stepwise
 - o 20-38% of women with eclampsia did not have preceding HTN or proteinuria
 - 78-83% had neurologic sx (severe/persistent HA, visual changes)
- Don't forget postpartum
 - HELLP: 30% of cases first expressed or progress postpartum
 - Most common first week, but at risk up to 6 weeks
- Consider ddx
 - Acute fatty liver of pregnancy: Rare condition characterized by severe liver dysfunction in pregnancy; markedly elevated LFTs; can lead to liver failure, requires immediate delivery
 - TTP/HUS (hemolysis, thrombocytopenia, renal dysfunction)
 - The usual causes of renal or hepatic dysfunction (substance use, viral hepatitis, etc)

COVID and Pregnancy

- People who are pregnant or recently pregnant are at an increased risk for severe illness from COVID-19, as well as for pregnancy complications (including preterm birth, stillbirth, preeclampsia)
 - Low threshold for transfer and inpatient care
- Depending on your site and policies, if a pregnant patient presents with respiratory distress or chest pain (and no OB complaints) may be better to stabilize in the ED (versus L&D)

COVID and Pregnancy

ARE YOU EXPECTING? FOUR REASONS TO GET THE COVID-19 VACCINE PREGNANT PEOPLE ARE MORE LIKELY TO GET EXTREMELY SICK FROM COVID-19 THAN OTHERS. THE ANTIBODIES THAT YOUR BODY MAKES IN RESPONSE TO THE VACCINE WILL TRANSFER TO YOUR BABY. MORE THAN 170,000 PREGNANT PEOPLE IN THE U.S. HAVE SAFELY RECEIVED THE COVID-19 VACCINES. GETTING THE VACCINE HAS NO EFFECT ON FERTILITY, & WILL NOT AFFECT YOUR ABILITY TO GET PREGNANT IN THE FUTURE. TO LEARN MORE VISIT: ONEVAXTWOLIVES.COM

- Vaccines (and boosters) are safe and recommended in pregnancy!
 - We should counsel patients on this at every possible point of care
 - #onevaxtwolives campaign—the passive immunity argument
- Depending on site policies and availability, pregnant women otherwise meeting criteria should be offered monoclonal antibodies for prevention of severe disease.

Thank you!

ACOG Safe Motherhood Initiative: Severe Hypertension in Pregnancy Bundle: https://www.acog.org/community/districts-and-sections/district-ii/programs-and-resources/safe-motherhood-initiative/severe-hypertension

ACOG PB 222: Gestational Hypertension and Preeclampsia (June 2020)

Creogs over Coffee: Hypertension and Pregnancy Trio (March 2019): https://creogsovercoffee.com/notes/2019/3/3/hypertension-and-pregnancy-trio

California Maternal Quality Care Collaborative: Eclampsia Algorithm https://www.cmqcc.org/resource/preeclampsia-toolkit-appendix-e-eclampsia-algorithm